Discovery Labs (DSCO +9.4%) shoots up on chatter that the firm may be in line to land FDA...


Discovery Labs (DSCO +9.4%) shoots up on chatter that the firm may be in line to land FDA approval on Surfaxin for the treatment of respiratory illness in infants.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs